Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.82 |
| ▸ | JAK1 | P23458 | 12/20 | 0.82 |
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 4/20 | 0.56 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.54 |
| ▸ | CDK9 | P50750 | 3/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341506 | 0.93 | JAK3 (0.82) | JAK3JAK1CDK2CCNE2CCNE1 | |
| SCHEMBL341531 | 0.92 | JAK1 (0.70) | JAK3JAK1CDK2CCNE2CCNE1 | |
| SCHEMBL341663 | 0.92 | JAK3 (0.69) | JAK3JAK1CDK2CCNE2CCNE1 | |
| SCHEMBL342001 | 0.90 | JAK3 (1.00) | JAK3JAK1CDK2SYKCDK1 | |
| SCHEMBL340016 | 0.87 | JAK1 (0.62) | JAK3JAK1CDK2CCNE1SYK | |
| SCHEMBL341022 | 0.85 | JAK3 (0.81) | JAK3JAK1CDK2CCNE2CCNE1 | |
| SCHEMBL341846 | 0.85 | JAK1 (0.60) | JAK3JAK1CDK2SYKCDK1 | |
| SCHEMBL339588 | 0.85 | JAK3 (0.61) | JAK3JAK1CDK2SYKCDK1 | |
| SCHEMBL340759 | 0.85 | JAK1 (0.70) | JAK3JAK1CDK2CCNE2CCNE1 | |
| SCHEMBL341200 | 0.84 | JAK1 (0.58) | JAK3JAK1SYKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9248132-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307515-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-9084795-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| EP-2389372-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8037782-B2 | Steering column assembly | FUJI KIKO CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20150307515-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885CDK2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.